More studies are needed to evaluate the validity of TEG in the prediction of bleeding risk and the safety of this regional technique in a mildly coagulopathic patients.”
“Systemic
lupus erythematosus in some cases is characterized for development of thrombotic events with a significantly increased risk of mortality. The frequencies and clinical associations of Ser(413)/Cys(413) PAI-2 polymorphism in 40 systemic lupus erythematosus, 50 rheumatoid arthritis patients, and 100 healthy subjects frequency were investigated. The Ser(413)/Ser(413) genotype was 53% (lupus), 36% (rheumatoid arthritis), and 35% (healthy subjects). The Ser(413) allele was associated with systemic lupus erythematosus (P =.04, odds ratio 1.76, 95% confidence interval = 1,01-3.06). PI3K inhibitor In all, 4 patient carriers of Ser(413)/Ser(413) genotype, developed thrombotic events. The lupus patients identified with Ser(413)/Ser(413) genotype showed an increased damage (57%), compared with Ser(413)/Cys(413) and Cys(413)/Cys(413)
genotypes, with significant difference (P =.03). These findings suggest an association ATM Kinase Inhibitor of Ser(413)/Ser(413) genotype with greater damage index score and Ser(413) allele with Systemic lupus erythematosus. Besides, PAI-2 polymorphism Could be related with thrombotic phenomena in systemic lupus erythematosus”
“Background: Cardiovascular diseases represent the major cause of mortality in hemodialysis (HD) patients. HD increases oxidative stress and oxidation of low-density lipoprotein (LDL) is a crucial step in the development of atherosclerosis. Vitamin E has been shown to reduce LDL oxidation. Our aim was to test the effect of a single HD BTSA1 inhibitor session and chronic vitamin E supplementation on LDL oxidizability in HD patients.
Methods: LDL susceptibility to copper-induced oxidation (lag-phase, LP) was measured in 19 HD patients, both immediately before and after hemodialysis; 18 age-matched healthy subjects served as controls. Both pre-HD and post-HD measurements were repeated after 12 weeks of vitamin E supplementation (800 IU/day)
in a placebo-controlled, randomized design.
Results: At baseline, HD patients showed hypertriglyceridemia, a significant triglyceride enrichment in LDL and HDL and an enhanced LDL resistance to oxidation (186 +/- 6 vs. 163 +/- 4 min, p<0.003). A single HD session decreased (to 172 +/- 6 min, or -8%, p<0.002), and chronic vitamin E administration increased, LDL resistance to oxidation (+19%, p = 0.002 vs. placebo) without changing the serum lipid profile or lipoprotein lipid composition.
Conclusions: We conclude that in patients on chronic hemodialysis, hypertriglyceridemia and triglyceride enrichment of LDL and HDL particles are associated with increased resistance of LDL to in vitro oxidation despite the fact that each dialysis session acutely increases LDL oxidizability. Vitamin E supplementation improves LDL resistance to oxidation without modifying circulating lipid levels and partitioning.